Baseline clinical characteristics of ER-CHOP patients and SPORE patients
| . | ER-CHOP (n = 107), no. (%) . | SPORE R-CHOP (n = 215), no. (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 62 (21-82) | 62 (21-92) | |
| Age ≥ 60 y | 58 (54) | 121 (56) | .72 |
| Sex, female | 48 (45) | 100 (47) | .78 |
| PS 0 or 1 | 94 (88) | 179 (83) | .28 |
| Stage III or IV | 86 (80) | 144 (67) | .01 |
| Elevated LDH | 72 (67) | 118 (58) | .13 |
| ≥ 2 extranodal sites | 32 (30) | 55 (26) | .45 |
| IPI | |||
| 0-1 | 25 (23) | 61 (28) | .33 |
| 2 | 27 (25) | 63 (29) | |
| 3 | 41 (38) | 61 (28) | |
| 4-5 | 14 (13) | 30 (14) | |
| 0-2 | 52 (49) | 124 (58) | |
| 3-5 | 55 (51) | 91 (42) | |
| B symptoms | 45 (42) | 64 (30) | .12 |
| Bulky disease (> 10 cm) | 19 (18) | 33 (15) | .62 |
| . | ER-CHOP (n = 107), no. (%) . | SPORE R-CHOP (n = 215), no. (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 62 (21-82) | 62 (21-92) | |
| Age ≥ 60 y | 58 (54) | 121 (56) | .72 |
| Sex, female | 48 (45) | 100 (47) | .78 |
| PS 0 or 1 | 94 (88) | 179 (83) | .28 |
| Stage III or IV | 86 (80) | 144 (67) | .01 |
| Elevated LDH | 72 (67) | 118 (58) | .13 |
| ≥ 2 extranodal sites | 32 (30) | 55 (26) | .45 |
| IPI | |||
| 0-1 | 25 (23) | 61 (28) | .33 |
| 2 | 27 (25) | 63 (29) | |
| 3 | 41 (38) | 61 (28) | |
| 4-5 | 14 (13) | 30 (14) | |
| 0-2 | 52 (49) | 124 (58) | |
| 3-5 | 55 (51) | 91 (42) | |
| B symptoms | 45 (42) | 64 (30) | .12 |
| Bulky disease (> 10 cm) | 19 (18) | 33 (15) | .62 |